Literature DB >> 25962016

Functional specificity of Akt isoforms in cancer progression.

Anne-Marie Fortier, Eric Asselin, Monique Cadrin.   

Abstract

Akt/PKB kinases are central mediators of cell homeostasis. There are three highly homologous Akt isoforms, Akt1/PKBα, Akt2/PKBβ and Akt3/PKBγ. Hyperactivation of Akt signaling is a key node in the progression of a variety of human cancer, by modulating tumor growth, chemoresistance and cancer cell migration, invasion and metastasis. It is now clear that, to understand the mechanisms on how Akt affects specific cancer cells, it is necessary to consider the relative importance of each of the three Akt isoforms in the altered cells. Akt1 is involved in tumor growth, cancer cell invasion and chemoresistance and is the predominant altered isoform found in various carcinomas. Akt2 is related to cancer cell invasion, metastasis and survival more than tumor induction. Most of the Akt2 alterations are observed in breast, ovarian, pancreatic and colorectal carcinomas. As Akt3 expression is limited to some tissues, its implication in tumor growth and resistance to drugs mostly occurs in melanomas, gliomas and some breast carcinomas. To explain how Akt isoforms can play different or even opposed roles, three mechanisms have been proposed: tissue-specificity expression/activation of Akt isoforms, distinct effect on same substrate as well as specific localization through the cyto-skeleton network. It is becoming clear that to develop an effective anticancer Akt inhibitor drug, it is necessary to target the specific Akt isoform which promotes the progression of the specific tumor.

Entities:  

Year:  2011        PMID: 25962016     DOI: 10.1515/bmc.2011.003

Source DB:  PubMed          Journal:  Biomol Concepts        ISSN: 1868-5021


  10 in total

Review 1.  The unconventional role of Akt1 in the advanced cancers and in diabetes-promoted carcinogenesis.

Authors:  Abdulrahman Alwhaibi; Arti Verma; Mir S Adil; Payaningal R Somanath
Journal:  Pharmacol Res       Date:  2019-05-09       Impact factor: 7.658

Review 2.  Targeting AKT for cancer therapy.

Authors:  Maryam Shariati; Funda Meric-Bernstam
Journal:  Expert Opin Investig Drugs       Date:  2019-10-12       Impact factor: 6.206

3.  Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation.

Authors:  Anne-Marie Fortier; Eric Asselin; Monique Cadrin
Journal:  J Biol Chem       Date:  2013-02-28       Impact factor: 5.157

4.  Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.

Authors:  Xiaoqing Zhang; Junwei Fan; Yuping Li; Shengtao Lin; Ping Shu; Jian Ni; Shengying Qin; Zhemin Zhang
Journal:  Tumour Biol       Date:  2015-08-14

5.  Role of the PI3K/AKT pathway and PTEN in otitis media.

Authors:  Hwan Ho Lee; Anthony Chin; Kwang Pak; Stephen I Wasserman; Arwa Kurabi; Allen F Ryan
Journal:  Exp Cell Res       Date:  2019-12-13       Impact factor: 3.905

Review 6.  Pancreatic Ductal Adenocarcinoma: MicroRNAs Affecting Tumor Growth and Metastasis in Preclinical In Vivo Models.

Authors:  Ulrich H Weidle; Fabian Birzele; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

7.  Giant obscurins regulate the PI3K cascade in breast epithelial cells via direct binding to the PI3K/p85 regulatory subunit.

Authors:  Marey Shriver; Saravanakumar Marimuthu; Colin Paul; Janelle Geist; Tessa Seale; Konstantinos Konstantopoulos; Aikaterini Kontrogianni-Konstantopoulos
Journal:  Oncotarget       Date:  2016-07-19

8.  AKT3 drives adenoid cystic carcinoma development in salivary glands.

Authors:  Katalin Zboray; Julian Mohrherr; Patricia Stiedl; Klemens Pranz; Laura Wandruszka; Beatrice Grabner; Robert Eferl; Richard Moriggl; Dagmar Stoiber; Kazuhito Sakamoto; Kay-Uwe Wagner; Helmut Popper; Emilio Casanova; Herwig P Moll
Journal:  Cancer Med       Date:  2017-12-28       Impact factor: 4.452

Review 9.  PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics.

Authors:  Alia Ghoneum; Neveen Said
Journal:  Cancers (Basel)       Date:  2019-07-05       Impact factor: 6.639

Review 10.  PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer.

Authors:  Kunrui Zhu; Yanqi Wu; Ping He; Yu Fan; Xiaorong Zhong; Hong Zheng; Ting Luo
Journal:  Cells       Date:  2022-08-12       Impact factor: 7.666

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.